US 11566041
Nucleotide prodrug compounds
granted A61KA61K31/706A61K9/007
Quick answer
US patent 11566041 (Nucleotide prodrug compounds) held by Ligand Pharmaceuticals Incorporated expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ligand Pharmaceuticals Incorporated
- Grant date
- Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/706, A61K9/007, A61P, A61P31/12